Cardio Diagnostics Holdings, Inc. Enters Into a Nationwide Telehealth Agreement with Navierre

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announces a strategic partnership with Navierre, an innovative digital health technology platform which revolutionizes how patients access healthcare and serves as a true health companion for every stage from birth to the golden years with a robust care navigation, wellness, and chronic care management offering. This collaboration aims to significantly expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests.

Heart disease remains the leading cause of death globally, underscoring the critical need for accessible and innovative clinical cardiovascular solutions. Current solutions for assessing the risk for and diagnosing heart disease such as CT imaging are not highly scalable due to the need for specialized infrastructure that is not readily available nationwide, especially in rural America. In contrast, Cardio Diagnostics’ clinical tests, Epi+Gen CHD and PrecisionCHD, that only require a blood sample that can be collected in provider settings, at-home or via mobile phlebotomy, can be scaled nationwide rapidly with minimal to no infrastructure barriers. By leveraging the rapidly growing telehealth market, Cardio Diagnostics in partnership with Navierre is poised to revolutionize the patient cardiovascular care journey through earlier detection, accessible specialty care, and personalized prevention.

Cardio Diagnostics' suite of AI-driven solutions, including the Epi+Gen CHD and PrecisionCHD tests, leverage cutting-edge epigenetic and genetic science to provide personalized insights into a patient's risk for coronary heart disease or coronary heart disease status. By identifying risk earliery and understanding the drivers of the risk, these tests provide actionable insights so patients and clinicians can take proactive steps towards prevention and management, ultimately improving outcomes and saving lives. Through the Navierre partnership, these transformative tools will now be accessible to a broader audience, breaking down barriers to specialty cardiovascular care.

Starting April 1, 2024, Cardio Diagnostics' precision heart health tests, including its flagship AI-powered epigenetic-genetic cardiovascular risk, detection, and management tests, will be available to thousands of patients and clinicians through Navierre's platform. Navierre-partnered clinicians across the United States can seamlessly order these tests for their patients, and consumers can easily register for a profile on the platform to fill out a health questionnaire and request the clinical test.